Kariya and NeuraLight Collaborate to Evaluate Brain Effects of Next-Generation GLP-1 Therapies
Kariya Pharmaceuticals and NeuraLight have announced a strategic partnership aimed at advancing the development of next-generation brain-focused GLP-1 therapies for neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease. The collaboration combines Kariya’s investigational brain-penetrant GLP-1/GIP therapy, KP405, with NeuraLight’s precision biomarker platform designed to measure brain function and neuroprotective effects in clinical trials.
The partnership reflects growing momentum within the pharmaceutical and biotechnology industries around the potential use of GLP-1 receptor agonists in neurological disorders. Originally developed and widely prescribed for diabetes and obesity, GLP-1 therapies have increasingly attracted scientific interest for their possible neuroprotective properties and their potential role in slowing neurodegeneration.
Under the agreement, NeuraLight’s digital biomarker platform will be integrated into Kariya’s upcoming Phase II clinical program evaluating KP405, a first-in-class dual GLP-1/GIP receptor agonist specifically engineered to cross the blood-brain barrier. The biomarker platform will be used to objectively quantify brain function and assess whether the investigational therapy is preserving neural activity and slowing neurodegenerative decline.
The collaboration represents an important step in the evolving effort to develop therapies that not only address symptoms of neurodegenerative diseases but also potentially modify disease progression itself. Researchers and clinicians have long sought reliable methods to measure neuroprotection in real time, and the combination of brain-penetrant therapeutics with advanced biomarker technologies may help address one of the field’s biggest challenges.
GLP-1 receptor agonists have emerged as one of the most successful drug classes in metabolic medicine over the past decade. Widely used in the treatment of type 2 diabetes and obesity, these therapies help regulate blood sugar, improve insulin sensitivity, and support weight reduction. However, scientists have increasingly recognized strong biological links between metabolic dysfunction and neurodegenerative disorders such as Parkinson’s disease and Alzheimer’s disease.
Emerging research suggests that impaired glucose metabolism, insulin resistance, neuroinflammation, and mitochondrial dysfunction may all contribute to the progression of neurodegenerative diseases. Because GLP-1 therapies influence several of these biological pathways, they have become promising candidates for neurological applications.
Researchers believe GLP-1 receptor activation may help restore impaired insulin signaling in the brain, reduce inflammation, improve neuronal energy utilization, and promote neuronal survival. In addition, GLP-1 activity is thought to enhance glucose transport into neurons, potentially reducing cellular energy deficits that contribute to neuronal injury and degeneration.
Over the past several years, clinical evidence supporting the neurological potential of GLP-1 therapies has steadily expanded. One notable study referenced in the announcement is the LIXIPARK trial, led by Olivier Rascol. The trial became one of the first large-scale GLP-1 studies to demonstrate superiority over placebo in improving motor outcomes among Parkinson’s disease patients.
Another influential study was the ELAD trial, which was published in Nature Medicine. The study showed that Alzheimer’s disease patients treated with liraglutide experienced slower cognitive decline and reduced brain atrophy compared with placebo-treated patients. The trial was co-authored by Christian Hölscher, a prominent researcher in neurodegenerative disease and GLP-1 biology.
Despite encouraging signals from earlier studies, more recent late-stage trials involving semaglutide for Alzheimer’s disease and exenatide for Parkinson’s disease failed to meet their primary endpoints. Importantly, neither of those therapies was originally designed to efficiently penetrate the brain.
According to researchers in the field, those trial outcomes provided valuable insight rather than invalidating the therapeutic approach altogether. One major emerging hypothesis is that the amount of drug successfully reaching the brain may directly influence therapeutic benefit in neurodegenerative conditions.
Traditional GLP-1 drugs were primarily optimized for metabolic effects in peripheral tissues rather than central nervous system delivery. As a result, researchers increasingly believe that future success in neurodegenerative disease treatment may depend on therapies specifically engineered for brain penetration and paired with tools capable of measuring actual neuroprotective effects.
This scientific rationale forms the foundation of Kariya’s development strategy for KP405. Unlike conventional GLP-1 therapies developed for diabetes and obesity, KP405 was specifically engineered to cross the blood-brain barrier and directly target neurological pathways involved in neurodegeneration.
KP405 is a dual GLP-1/GIP receptor agonist that incorporates a specialized cell-penetrating peptide designed to actively transport the drug into the brain. Once in the central nervous system, the therapy activates complementary receptor pathways intended to reduce neuroinflammation, improve neuronal survival, and protect brain cells from progressive degeneration.
The dual agonist approach is considered particularly promising because GIP receptor activation may provide additional neuroprotective and metabolic benefits beyond GLP-1 signaling alone. Researchers are increasingly exploring combined incretin therapies as potential next-generation approaches for both metabolic and neurological disorders.
Kariya has already completed Phase I clinical development for KP405, establishing an initial safety and tolerability profile. The company is now preparing to advance the therapy into Phase II testing, where the integration of NeuraLight’s biomarker platform is expected to provide deeper insight into whether the therapy is producing measurable preservation of brain function.
Ian Laquian described the collaboration as a major milestone for the company’s clinical development efforts. He stated that combining KP405 with NeuraLight’s precision biomarker technology positions the therapy to more effectively translate promising biological mechanisms into meaningful clinical outcomes for patients with Parkinson’s disease and potentially other neurodegenerative conditions.
Laquian emphasized that the partnership could help strengthen the scientific and clinical foundation of the Phase II program by providing objective measurements of neuroprotection rather than relying solely on conventional symptom-based clinical endpoints.
NeuraLight’s technology platform is designed to generate highly precise measures of brain function using advanced digital biomarkers and artificial intelligence-driven analysis. The company focuses on developing tools capable of quantifying neural pathway activity and functional changes across a range of central nervous system disorders, including Parkinson’s disease and Alzheimer’s disease.
For neuroprotective therapies like KP405, the platform may provide a way to directly evaluate whether brain function is being preserved during treatment. This type of quantitative assessment is considered increasingly important in neurodegenerative drug development, where demonstrating disease modification has historically been difficult.
Edmund Ben-Ami noted that the ability to objectively measure whether a therapy is preserving brain function may be essential for unlocking the full potential of GLP-1 therapies in neurodegenerative diseases.
Ben-Ami stated that Kariya designed KP405 specifically for efficient brain delivery, while NeuraLight developed its platform to determine whether such delivery translates into measurable functional preservation. According to him, the partnership combines two complementary innovations that may help advance the field toward more effective treatments for neurodegenerative diseases.
The collaboration also highlights a broader shift occurring across neuroscience drug development. Pharmaceutical companies and biotechnology firms are increasingly combining therapeutics with advanced digital biomarkers, artificial intelligence, and precision medicine technologies to improve clinical trial design and enhance the ability to detect meaningful treatment effects earlier in development.
Neurodegenerative diseases remain among the most challenging areas in medicine, with high clinical trial failure rates and limited disease-modifying treatment options currently available. Alzheimer’s disease and Parkinson’s disease affect millions of patients globally, and the economic and societal burden associated with these disorders continues to rise as populations age.
As scientific understanding of the relationship between metabolism and neurodegeneration continues to evolve, therapies targeting metabolic pathways are gaining increasing attention within the neuroscience community. Brain-penetrant incretin therapies like KP405 represent one of the newest and potentially most promising areas of investigation.
By combining targeted drug delivery with advanced biomarker measurement technologies, Kariya Pharmaceuticals and NeuraLight hope to establish a more precise and data-driven approach to evaluating neuroprotective therapies. Industry observers believe such integrated strategies may ultimately improve the ability to identify successful treatments and accelerate the development of new therapies for patients living with devastating neurodegenerative disorders.
About Kariya Pharmaceuticals
Kariya Pharmaceuticals is a clinical-stage biotechnology company developing brain-penetrant therapeutics to slow the progression of neurodegenerative disease. Its lead asset, KP405, is a first-in-class, brain-penetrant, dual GLP-1/GIP receptor agonist engineered to enhance cellular energetics, improve insulin signaling, and reduce neuroinflammation in Parkinson’s and Alzheimer’s disease. KP405 has demonstrated clear superiority over existing incretin analogues across multiple preclinical models of neurodegeneration, and recently completed a Phase I SAD/MAD program with a favorable safety and tolerability profile consistent with the broader GLP-1 class. Headquartered in Copenhagen, Denmark, Kariya is now advancing KP405 into Phase II development. For more information, visit www.kariyapharma.com.
About NeuraLight
NeuraLight is a healthtech company on a mission to make brain function accurately measurable and actionable. Fusing decades of world-class neuroscience research with a breakthrough AI engine and proprietary data, the NeuraLight platform sets a new standard by quantifying core aspects of brain function at scale. NeuraLight’s technology is embedded in multiple commercial partnerships and endorsed by leading neurologists, Nobel laureates and major research foundations, establishing it as a prominent infrastructure for the future of brain health. For more information, visit www.neuralight.ai.
